The NTRK2 antibody is a crucial tool in neuroscience and oncology research, targeting the neurotrophic receptor tyrosine kinase 2 (NTRK2), also known as TrkB. NTRK2 is a high-affinity receptor for brain-derived neurotrophic factor (BDNF) and neurotrophin-4 (NT-4), playing a pivotal role in neuronal survival, differentiation, synaptic plasticity, and cognitive functions. Dysregulation of NTRK2 signaling is implicated in neurological disorders (e.g., Alzheimer’s disease, depression) and cancers, particularly those with NTRK gene fusions that drive oncogenesis. The antibody detects endogenous NTRK2 protein, enabling studies on its expression, localization, and activation mechanisms in tissues or cell lines. It is widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence. Researchers also leverage NTRK2 antibodies to explore therapeutic strategies, such as inhibiting TrkB in BDNF-driven tumors or enhancing its activity in neurodegenerative contexts. As NTRK inhibitors (e.g., larotrectinib) gain traction in precision oncology, NTRK2 antibodies serve as companion diagnostics to identify patients with NTRK alterations. However, specificity challenges due to TrkB splice variants or cross-reactivity with other Trk receptors (TrkA, TrkC) necessitate rigorous validation. Overall, NTRK2 antibodies bridge basic research and clinical translation in neurobiology and cancer.